Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sarah B Goldberg

Showing results (71-80 of 106) with videos related to

Pageof 11
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 11, 2012
A phase I study of erlotinib and hydroxychloroquine in advanced non-small-cell lung cancerSarah B Goldberg, Jeffrey G Supko, Joel W Neal, et al.
Molecular Cancer|May 29, 2026
NSCLC brain metastases exhibit reduced HLA-I antigen presentation machinery and immune evasion independent of IFNγ signaling defectsNoelia Vilariño, Miguel López de Rodas, Maria Villalba-Esparza, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 6, 2026
Genomic Profiling of Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer Post-Progression on First-Line Osimertinib: Phase II ORCHARD StudyHelena A Yu, Kwan Ho Tang, Aleksandra A Markovets, et al.
Cancer Treatment Reviews|August 16, 2024
Central nervous system metastases in advanced non-small cell lung cancer: A review of the therapeutic landscapeMichael Weller, Jordi Remon, Stefan Rieken, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 9, 2018
Long-Term Survival of Patients With Melanoma With Active Brain Metastases Treated With Pembrolizumab on a Phase II TrialHarriet M Kluger, Veronica Chiang, Amit Mahajan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 6, 2020
Randomized Trial of Afatinib Plus Cetuximab Versus Afatinib Alone for First-Line Treatment of <i>EGFR</i>-Mutant Non-Small-Cell Lung Cancer: Final Results From SWOG S1403Sarah B Goldberg, Mary W Redman, Rogerio Lilenbaum, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 23, 2025
Osimertinib Plus Savolitinib in Patients With EGFR-Mutated Advanced NSCLC With MET Alterations After First-Line Osimertinib: Clinical Outcomes, Safety, and Biomarker Analysis: A Brief ReportXiuning Le, Christina Baik, Byoung Chul Cho, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 5, 2023
Brief Report: Safety and Antitumor Activity of Durvalumab Plus Tremelimumab in Programmed Cell Death-(Ligand)1-Monotherapy Pretreated, Advanced NSCLC: Results From a Phase 1b Clinical TrialEdward B Garon, Alexander I Spira, Sarah B Goldberg, et al.
European Journal of Cancer (Oxford, England : 1990)|May 27, 2026
Osimertinib plus selumetinib in patients with EGFR-mutated advanced NSCLC with BRAF alterations post-progression on first-line osimertinib: ORCHARDZofia Piotrowska, Sarah B Goldberg, Jonathan W Goldman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 6, 2025
Quantitative Protein Expression of Antibody-Drug Conjugate Targets in EGFR Mutated and Wild-Type Non-Small Cell Lung CancerIoannis P Trontzas, Mengni He, Anna Wurtz, et al.
Pageof 11

Showing results (71-80 of 106) with videos related to

Sort By:
Pageof 11
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 11, 2012
A phase I study of erlotinib and hydroxychloroquine in advanced non-small-cell lung cancerSarah B Goldberg, Jeffrey G Supko, Joel W Neal, et al.
Molecular Cancer|May 29, 2026
NSCLC brain metastases exhibit reduced HLA-I antigen presentation machinery and immune evasion independent of IFNγ signaling defectsNoelia Vilariño, Miguel López de Rodas, Maria Villalba-Esparza, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 6, 2026
Genomic Profiling of Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer Post-Progression on First-Line Osimertinib: Phase II ORCHARD StudyHelena A Yu, Kwan Ho Tang, Aleksandra A Markovets, et al.
Cancer Treatment Reviews|August 16, 2024
Central nervous system metastases in advanced non-small cell lung cancer: A review of the therapeutic landscapeMichael Weller, Jordi Remon, Stefan Rieken, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 9, 2018
Long-Term Survival of Patients With Melanoma With Active Brain Metastases Treated With Pembrolizumab on a Phase II TrialHarriet M Kluger, Veronica Chiang, Amit Mahajan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 6, 2020
Randomized Trial of Afatinib Plus Cetuximab Versus Afatinib Alone for First-Line Treatment of <i>EGFR</i>-Mutant Non-Small-Cell Lung Cancer: Final Results From SWOG S1403Sarah B Goldberg, Mary W Redman, Rogerio Lilenbaum, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 23, 2025
Osimertinib Plus Savolitinib in Patients With EGFR-Mutated Advanced NSCLC With MET Alterations After First-Line Osimertinib: Clinical Outcomes, Safety, and Biomarker Analysis: A Brief ReportXiuning Le, Christina Baik, Byoung Chul Cho, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 5, 2023
Brief Report: Safety and Antitumor Activity of Durvalumab Plus Tremelimumab in Programmed Cell Death-(Ligand)1-Monotherapy Pretreated, Advanced NSCLC: Results From a Phase 1b Clinical TrialEdward B Garon, Alexander I Spira, Sarah B Goldberg, et al.
European Journal of Cancer (Oxford, England : 1990)|May 27, 2026
Osimertinib plus selumetinib in patients with EGFR-mutated advanced NSCLC with BRAF alterations post-progression on first-line osimertinib: ORCHARDZofia Piotrowska, Sarah B Goldberg, Jonathan W Goldman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 6, 2025
Quantitative Protein Expression of Antibody-Drug Conjugate Targets in EGFR Mutated and Wild-Type Non-Small Cell Lung CancerIoannis P Trontzas, Mengni He, Anna Wurtz, et al.
Pageof 11